Latest news with #mNGS
Business Wire
18 hours ago
- Health
- Business Wire
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
BOSTON--(BUSINESS WIRE)-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. "Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not and speed is critical' said Brad Murray, chief executive officer of Delve Bio. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. 'This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup,' said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. 'This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections.' The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? 'These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical,' said Brad Murray, chief executive officer of Delve Bio. 'We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need.' Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit
Associated Press
07-04-2025
- Health
- Associated Press
Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, will share data about its groundbreaking mNGS test, Delve Detect, at the 2025 American Academy of Neurology Annual Meeting today in San Diego. With the ability to identify more than 68,000 pathogens with a single test, Delve's mNGS technology delivers greater diagnostic yield over conventional methods of diagnosing meningitis and encephalitis. 'Diagnosing meningitis and encephalitis has historically required running test after test as physicians try to determine which pathogen is causing a patient's infection. In more than half of those cases, the cause is never found,' said Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'By using a metagenomic test, clinicians can detect viruses, bacteria, parasites, and fungi in just one test. It's an approach with more than seven years of real world evidence behind it showing mNGS outperforms traditional testing methods by over 20%, helping solve complex cases faster.' At this year's AAN Annual Meeting, Delve is presenting its mNGS assay and the technology behind Delve Detect. The backbone of Delve's mNGS platform is Delve Decide, which enables sequence matching of DNA and RNA to a curated database of over 68,000 pathogens through robust bioinformatic analysis, validated QC metrics, dynamic filtering, and visualization of high-quality reads; the results receive expert clinical interpretation to deliver comprehensive microbial analysis impossible through conventional testing. The strength of Delve's approach has been demonstrated through data from more than 4,800 patients tested at the University of California San Francisco (UCSF) over seven years – the largest study of its kind. The study found mNGS identified more pathogens than all other traditional methods (culture, antigen testing, PCR, and serology) combined. Published in Nature Medicine, the data showed mNGS detected pathogens in 14.4% of samples, representing 437 unique pathogen species, including DNA and RNA viruses, bacteria, fungi, and parasites. Among a subset of more than 1,000 patients treated at UCSF, 21.8% (48 of 220) of infections were identified by mNGS alone. Delve Detect is the company's flagship testing service, providing comprehensive test results with a 48-hour turnaround time after sample receipt and access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts to review results in clinical context. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit Amy Wong Senior Director of Marketing and Business Development, Delve Bio Media 42 North for Delve Bio INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES NEUROLOGY CLINICAL TRIALS RESEARCH SCIENCE SOURCE: Delve Bio, Inc. Copyright Business Wire 2025. PUB: 04/07/2025 07:27 AM/DISC: 04/07/2025 07:26 AM
